ConductScience.org, home

Paper32943751

Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study.

Yang Y and 27 others. Leukemia, 2021. Cited by 30 papers, by iCite.

Cite this record

ConductScience Library. Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study. Papers, record 32943751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32943751

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study.
PubMed
Journal
Leukemia
PubMed
Year
2021
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
30
iCite
Relative citation ratio, by iCite
1.85
iCite
Revised in PubMed
2021-08-27
PubMed

Authors28

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yang YYong
2Wang YYing
3Liu XXin
4He XXia
5Zhang LLLi-Ling
6Wu GGang
7Qu BLBao-Lin
8Qian LTLi-Ting
9Hou XRXiao-Rong
10Zhang FQFu-Quan
11Qiao XYXue-Ying
12Wang HHua
13Li GFGao-Feng
14Zhu YYuan
15Cao JZJian-Zhong
16Wu JXJun-Xin
17Wu TTao
18Zhu SYSu-Yu
19Shi MMei
20Xu LMLi-Minghttps://orcid.org/0000-0001-9523-9062

Source PubMed

See all 28 authorsDownload CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Lymphoma, Extranodal NK-T-CellMajor topic
Adult
Combined Modality Therapy
Female
Follow-Up Studies
Humans
Male
Middle Aged
Prognosis
Retrospective Studies
Survival Rate

Source PubMed

Download CSV of topics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in34341480Correction to: Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study.https://conductscience.org/library/papers/34341480

Source PubMed

Download CSV of comments and corrections

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.

PMIDTitleJournalYearIn PapersSource
42591107Survival analysis and prognostic factors of mature T-cell and natural killer/T-cell neoplasms in Colombian patients from 2008-2025.Front Oncol2026https://conductscience.org/library/papers/42591107PubMed
42414740
Development and validation of a radiomics nomogram for predicting outcomes following combined radiotherapy and modern chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: a multicenter study.
Ann Hematol2026https://conductscience.org/library/papers/42414740PubMed
42400641The increased co-expression of SLC7A11 and PD-L1 was associated with poor prognosis in extranodal natural killer T-cell lymphoma patients.Cancer Immunol Immunother2026https://conductscience.org/library/papers/42400641PubMed
42154282Lactate dehydrogenase/albumin ratio predicts progression of disease within 24 months (POD24) in advanced-stage extranodal natural killer/T cell lymphoma.Ann Hematol2026https://conductscience.org/library/papers/42154282PubMed
42022040Development and validation of a multiparameter prognostic model for extranodal natural killer/T-cell lymphoma: Integration of clinical, pathological, and molecular biomarkers.Cytojournal2026https://conductscience.org/library/papers/42022040PubMed
41613778Failure patterns and clinical indications in early-stage follicular lymphoma: a study from the National Cancer Center in China.Front Pharmacol2026https://conductscience.org/library/papers/41613778PubMed
41552766Synchronous primary pulmonary extranodal NK/T-cell lymphoma and relapsed Hodgkin lymphoma occurring after chemotherapy for primary Hodgkin lymphoma: A case report and literature review.Rare Tumors2026https://conductscience.org/library/papers/41552766PubMed
40115906Subsequent Survival and Loss of Lifetime for Patients With Progression-Free 24 Months After Treatment in Nasopharyngeal Carcinoma: A Comprehensive Nationwide Population-Based Analysis.MedComm (2020)2025https://conductscience.org/library/papers/40115906PubMed
39144825Challenges in overcoming advanced-stage or relapsed refractory extranodal NK/T-cell lymphoma: meta-analysis of individual patient data.Front Oncol2024https://conductscience.org/library/papers/39144825PubMed
38783159Increased coexpression of PD-L1 and IDO1 is associated with poor overall survival in patients with NK/T-cell lymphoma.Leukemia2024https://conductscience.org/library/papers/38783159PubMed
38604793[Efficacy and safety analysis of P-GemDOx regimen and stratified prognosis in patients with early extranodal NK/T cell lymphoma].Zhonghua Xue Ye Xue Za Zhi2024https://conductscience.org/library/papers/38604793PubMed
38040859Clinical significance and predictive risk factors for event-free survival at 24 months in patients with PTCL, NOS.Ann Hematol2024https://conductscience.org/library/papers/38040859PubMed
37558851Prognostic value of POD18 combined with improved IELSG in primary central nervous system lymphoma.Clin Transl Oncol2024https://conductscience.org/library/papers/37558851PubMed
37351807Comparative analysis of upper aerodigestive tract and non-upper aerodigestive tract in NK/T-cell lymphoma.Clin Transl Oncol2024https://conductscience.org/library/papers/37351807PubMed
37345104Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia.Cancers (Basel)2023https://conductscience.org/library/papers/37345104PubMed
37306711Outcome and risk prediction of early progression in patients with extranodal natural killer/T cell lymphoma from the CLCG study.Ann Hematol2023https://conductscience.org/library/papers/37306711PubMed
37181228Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: A randomized phase III study.Innovation (Camb)2023https://conductscience.org/library/papers/37181228PubMed
36951150Evidence of cure for extranodal nasal-type natural killer/T-cell lymphoma with current treatment: an analysis of the CLCG database.Haematologica2023https://conductscience.org/library/papers/36951150PubMed
36825002Treatment of extranodal NK/T-cell lymphoma: From past to future.Front Immunol2023https://conductscience.org/library/papers/36825002PubMed
36819187Characteristics and prognosis of distant metastasis after primary treatment for early-stage extranodal nasal-type natural killer/T-cell lymphoma from the China Lymphoma Collaborative Group database.EJHaem2023https://conductscience.org/library/papers/36819187PubMed

See all 23 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32943751

GET https://conductscience.org/api/papers/v1/32943751/authors?page=2